Objectives: The objective of this study was to evaluate the apparent diffusion coefficient (ADC) of diffusion-weighted magnetic resonance (MR) imaging for the differentiation of transition zone cancer from non-cancerous transition zone with and without prostatitis and for the differentiation of transition zone cancer Gleason grade (GG) using MR-guided biopsy specimens as a reference standard. Materials and Methods: From consecutive MR-guided prostate biopsies (2008Y2012) in our referral center, we retrospectively included patients from whom diffusion-weighted MR imaging ADC values were acquired during MR-guided biopsy and whose biopsy cores had a (cancer) core length 10 mm or greater and originated from the transition zone. Two radiologists, who were blinded to the ADC data, annotated regions of interest on biopsy sampling locations of MR-guided biopsy confirmation scans in consensus. Median ADC (mADC) of the regions of interest was related to histopathology outcome in MR-guided biopsy core specimens. Mixed model analysis was used to evaluate mADC differences between 7 histopathology categories predefined as MR-guided biopsy core specimens with primary and secondary GG 4Y5 (I), primary GG 4Y5 secondary GG 2Y3 (II), primary GG 2Y3 secondary GG 4Y5 (III) and primary and secondary GG 2Y3 cancer (IV), and noncancerous tissue without (V) or with degree 1 (VI) or degree 2 prostatitis (VII). Diagnostic accuracy was evaluated using areas under the receiver operating characteristic (AUC) curve. Results: Fifty-two patients with 87 cancer-containing biopsy cores and 53 patients with 101 non-cancerous biopsy cores were included. Significant mean mADC differences were present between cancers (mean mADC, 0.77Y0.86 Â 10 j3 mm 2 /s) and noncancerous transition zone without (1.12 Â 10 j3 mm 2 /s) and with degree 1 to 2 prostatitis (1.05Y1.12 Â 10 j3 mm 2 /s; P G 0.0001Y0.05). Exceptions were mixed primary and secondary GG cancers versus a degree 2 of prostatitis (P = 0.06Y0.09). No significant differences were found between subcategories of primary and secondary GG cancers (P = 0.17Y0.91) and between a degree 1 and 2 prostatitis and non-cancerous transition zone without prostatitis (P = 0.48Y0.94).
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The mADC had an AUC of 0.84 to differentiate cancer versus non-cancerous transition zone. AUCs of 0.84 and 0.56 were found for mADC to differentiate prostatitis from cancer and from non-cancerous transition zone. The mADC had an AUC of 0.62 to differentiate a primary GG 4 versus GG 3 cancer.
Conclusions:
The mADC values can differentiate transition zone cancer from non-cancerous transition zone and from a degree 1, and from most cases of a degree 2 prostatitis. However, because of substantial overlap, mADC has a moderate accuracy to differentiate between different primary and secondary GG subcategories and cannot be used to differentiate non-cancerous transition zone from degrees 1 to 2 of prostatitis. Diffusion-weighted imaging ADC may therefore contribute in the detection of transition zone cancers; however, as a single functional MR imaging technique, diffusion-weighted imaging has a moderate diagnostic accuracy in separating higher from lower GG transition zone cancers and in differentiating prostatitis from non-cancerous transition zone. 1 Based on radical prostatectomy and saturation biopsy specimens, at least 30% to 45% of diagnosed cancers are situated in the prostate transition zone. 2, 3 In patients with an elevated prostate-specific antigen (PSA) and cancer-negative transrectal ultrasound-guided biopsies, high proportions of transition zone cancer (57%Y63%) are detected upon magnetic resonance (MR)Yguided biopsy. 4, 5 The latter finding reflects that many transition zone cancers are missed by transrectal ultrasound-guided biopsy, probably because of undersampling of the ventral prostate transition zone. Performing MR imaging 6 and MR-guided biopsy in patients with an elevated PSA and negative transrectal ultrasound-guided biopsies may therefore improve detection of transition zone prostate cancer. However, upon MR imaging of the prostate transition zone, differentiation of prostate cancer from healthy tissue is difficult because of the overlap of signal intensities and quantitative parameters between prostate cancer and stromal benign prostatic hyperplasia. 7, 8 Prostate cancer should also be differentiated from prostatitis, which is often present also in the transition zone. 9 In prostatitis, inflammatory infiltrates may increase cellular density and may therefore decrease T2-weighted MR imaging signal intensity and diffusionweighted MR imaging apparent diffusion coefficient (ADC) values. For the peripheral zone, prostatitis can be differentiated from healthy tissue and from lowYGleason grade (GG) cancer; however, for the transition zone, differentiation of prostatitis from a high-GG cancer and from healthy tissue has not been described earlier. 10 Once a transition zone cancer is detected on MR imaging, accurate determination of its Gleason score is important because transition zone cancers are known to have lower Gleason scores and lower biochemical recurrence rates. 11 Lower diffusion-weighted imaging ADC values have been related to higher prostate cancer Gleason scores, predominantly for peripheral zone cancers. 12, 13 Most of these studies have been performed using radical prostatectomy specimens as a reference standard. However, exact alignment of MR imaging slices with prostatectomy specimen sections remains difficult because of differences in angulations of imaging slicing and specimen sectioning and because of prostate shrinkage during histopathology processing. Furthermore, observer bias is almost unavoidable in attributing a certain region of interest (ROI) on MR imaging to a tumor, which is identified in a prostatectomy specimen section.
14 Recently, size and positioning of an ROI were shown to influence tumor ADC measurements and interobserver variability in rectal cancer. 15 Magnetic resonanceYguided biopsy specimens may be a reference-standard alternative for radical prostatectomy specimens because the highest GG of an MR-guided biopsy specimen has a high concordance (88%) with the highest GG of the radical prostatectomy specimen. 16 This high concordance rate is caused by the ability of multiparametric MR imaging and especially of diffusionweighted MR imaging to predict and localize the cancer areas with the highest GG. 17 When using MR-guided biopsy as a reference standard, T2*-weighted gradient echo images, which confirm needle positioning, are available. 5 Locations where prostate cancer biopsy specimens were sampled can be determined from signal voids of the biopsy needle on these MR-guided biopsy confirmation scans. Because annotation of biopsy sampling areas on confirmation scans is unrelated to the ADC map, it may reduce observer bias in relating ADC values to MR-guided biopsy histopathology. Therefore, our purpose was to evaluate the ADC of diffusionweighted MR imaging for the differentiation of the transition zone cancer from the non-cancerous transition zone with and without prostatitis and for the differentiation of transition zone cancer GGs using MR-guided biopsy specimens as a reference standard.
MATERIALS AND METHODS Patients
The need for informed consent for this retrospective study was waived by the institutional review board. From all consecutively performed MR-guided biopsies between March 2008 and February 2012 in our referral center, we included patients using the following inclusion criteria:
-Performed diffusion-weighted imaging and ADC maps as part of the MR-guided biopsy procedure. -Magnetic resonanceYguided biopsy cores with prostate cancer in a cancer core length of 10 mm or greater and a transition zone location on MR-guided biopsy confirmation scans. A cancer core length of 10 mm or greater is 60% of a standard needle notch length of 17 mm and was chosen to limit variation because of mADC measurements in noncancerous tissue. By choosing this limit, at least 60% of the annotated ROI was related to prostate cancer. -Magnetic resonanceYguided biopsy cores without prostate cancer with a core length of 10 mm or greater and a transition zone location of the needle sample on MR-guided biopsy confirmation scans.
The exclusion criteria were an existing diagnosis of prostate cancer before the MR-guided biopsy (n = 50) or unavailable biopsy histopathology specimens from external hospitals (n = 5). Also, needle positions for which MR-guided biopsy core identification was impossible were excluded. The latter was caused by simultaneous unspecified sampling of more cores referred for histopathology analysis as 1 sample unit (n = 22) or caused by a lack of MR-guided biopsy confirmation scans with needle artifacts (n = 1) or caused by impossible accurate registration of the ADC map to the confirmation scans (n = 1). Patient selection is depicted in a flow diagram in Figure 1 .
Magnetic Resonance Imaging and MR-Guided Biopsy Acquisition
Two 3-T whole-body systems (MAGNETOM Trio and MAGNETOM Skyra; Siemens Medical Solutions, Erlangen, Germany) were used to perform MR imaging and MR-guided biopsy. An MRcompatible manual biopsy device, an endorectal needle guider, and an n.a.
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18-gauge biopsy gun (all from Invivo, Gainesville, FL) were used to perform the MR-guided biopsy. To detect prostate cancer, MR-guided biopsies were performed on the basis of the results of a previously performed multiparametric MR imaging examination, consisting of T2-weighted, diffusion-weighted, and dynamic contrast-enhanced MR imaging. 5 The multiparametric MR imaging and MR-guided biopsy sequence parameters are depicted in Table 1 . Two radiologists with 10 and 19 years of experience in prostate MR imaging (J.J.F. and J.O.B.) evaluated the initial MR images on a clinical software workstation while having access to patient data. 18 Cancer suspicious regions were defined as described earlier. 19 The patients received antibiotic prophylaxis of 2 daily doses of 500-mg ciprofloxacin orally for 3 days and the biopsy was performed on the second day. Biopsies were performed by 1 radiologist with 3 years (C.M.A.H.), 1 radiologist with 2 years (J.G.R.B.), and 1 radiologist (E.K.V.) with 1 year of experience in MR-guided biopsy. 19 Initially, T2-weighted MR imaging and diffusion-weighted imaging were performed for the re-identification of previously defined cancer suspicious regions. Consequently, sagittal and axial balanced gradient echo sequences were acquired during the repositioning of an endorectally inserted needle guide towards a cancer-suspicious region. When the needle guide was accurately targeted at a cancersuspicious region, biopsies were taken by insertion of the 18-gauge needle biopsy gun (In vivo, Schwerin, Germany) through the needle guide. Directly after the MR-guided biopsy with the needle situated in the prostate, gradient echo sequences were repeated to confirm the position of the (sampling part of the) needle in a cancer-suspicious region. Acquisition times for the transverse and sagittal confirmation scans for MAGNETOM Trio and Skyra were 8.9 and 9.0 seconds for the axial scans and 7.5 and 7.6 seconds for the sagittal scans, respectively.
Histopathology
Biopsy core specimens were directly fixated in formalin. The cores were fixated and analyzed separately. All cores were histopathologically re-evaluated by 1 experienced urogenital pathologist with 20 years of experience (C.A.H.), who was blinded to the MR imaging results. Gleason grade was evaluated using the 2005 International Society of Urological Pathology-modified Gleason grading criteria. 20 Prostatitis was defined as the presence of inflammatory infiltrates in the prostate. 21 A degree 1 (mild), 2 (moderate), and 3 (severe) prostatitis were respectively defined as follows: an MR-guided prostate biopsy specimen core tissue area involvement of 1 lower than 10% by inflammatory cell infiltrates consisting of individual cells, separated by distinct intervening spaces (G100 cells/mm 
21
Differentiation was made between chronic, chronic active, and granulomatous prostatitis. 21 
Annotation of MR-Guided Biopsy Confirmation Scans
Magnetic resonance-guided biopsy confirmation scans were analyzed with an in-houseYdeveloped software. 18 Two radiologists (one with 3 years [C.M.A.H.] and one with 1 year [E.K.V.] of experience in prostate MR imaging) annotated ROIs in consensus while they were blinded for histopathology results. In case of prostate displacement during the MR-guided biopsy procedure, the ADC maps were manually registered with the post-biopsy confirmation scans to correct for this displacement. Slices that most optimally represented the middle of the needle artifact were identified on both the sagittal and the transversal post-biopsy T2-weighted balanced gradient echo images. Subsequently, the presumed in vivo needle track of 22 mm was measured from the visible needle tip inside the signal void, taking into account a signal void of the needle artifact (2Y3 mm) in front of the needle trajectory. The last 17 mm of this 22 mm represented the needle notch, where the tissue core was obtained. This last 17 mm area was annotated on the transverse T2-weighted balanced gradient echo image. The notch length of 17 mm was annotated with overlapping ROIs (4.0 Â 4.0 Â 4.0 mm) matching the visible needle within the artifact signal void. An example of our annotation method is depicted in Figure 2 . The radiologists annotated all cores over the entire core length (17 mm) in all patients. In patients in whom the core sample involved extraprostatic tissue, only the core parts situated in the prostate were annotated. All ROIs of 1 notch length represented 1 core and were analyzed as a unit. For every annotated core, the mean, the SD, and the median ADC (mADC) were calculated by the software using the ADC values from all annotated ROIs in the core.
Statistics
The analyses were performed using Predictive Analytics SoftWare (PASW) Statistics version 18 (SPSS, Inc, Quarry Bay, Hong Kong). The threshold for significance was defined as P G 0.05. Differences in patient characteristics were evaluated using independent t tests for parametric continuous variables and the Mann-Whitney test for non-parametric continuous variables.
The ROI ADC was related to the histopathology outcome in MR-guided biopsy specimens, which served as a reference standard. Linear multilevel mixed model analysis was used to evaluate mADC differences for 7 histopathology categories, defined as MR-guided biopsy core specimens with a primary and secondary GG 4Y5 (I), primary GG 4Y5 secondary GG 2Y3 (II), a primary GG 2Y3 secondary GG 4Y5 (III) and primary and secondary GG 2Y3 cancer (IV) cancer, and noncancerous transition zone tissue without (V) or with degree 1 prostatitis (VI) or degree 2 prostatitis (VII). To correct for possible correlations between different cores coming from 1 patient, patients were used as a random factor in this model. Because non-cancerous parts in cancer-containing cores may have caused mADC variation, we compared mADC for cancer core lengths of respectively 10 to 12, 13 to 15, and greater than 15 mm.
Receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic accuracy for mADC to differentiate between predefined histopathological categories.
RESULTS
We included 87 MR-guided biopsy cores containing transition zone cancer in 52 patients and 101 non-cancerous transition zone cores in another 53 patients. Patient characteristics are depicted in Table 2 . For every patient, MR-guided biopsy cores were taken from 1 cancer-suspicious region. A patient example is depicted in Figure 3 .
Of the 87 cancer-containing cores, 27 cores had a primary and secondary GG 4Y5, 12 cores had a primary GG 4Y5 and a secondary GG 2Y3, 24 cores had a primary GG 2Y3 and a secondary GG 4Y5, and another 24 cores had both primary and secondary GG 2Y3. Of the 101 non-cancerous transition zone cores, 46 cores existed out of healthy transition zone tissue without prostatitis, 50 cores contained a degree 1 prostatitis (of which 88% [44/50] were of a chronic type and 12% [6/50] were of a chronic active type), and 5 cores involved prostatitis up to a degree of 2 (2 of the chronic and 3 of the chronic active type). Because the subtotals of cores with a chronic (active) type of prostatitis were very small, no further analyses were performed to differentiate between the chronic and chronic active types of prostatitis.
For patients with transition zone cancer, MR-guided biopsy core lengths ranged from 12.0 to 16.0 mm (interquartile range) and were invaded by cancer (cancer core length) in a length of (interquartile range) 11.0 to 14.0 mm. Core length of the non-cancerous MR-guided biopsy specimens ranged from 10.3 to 15.0 mm.
Upon linear mixed model analysis, significant mADC differences were present between transition zone cancers (mean mADC, 0.77Y0.86 Â 10 j3 mm 2 /s) and non-cancerous transition zone without (1.12 Â 10 j3 mm 2 /s) and with degrees 1 to 2 prostatitis (1.05Y1.12 Â 10 j3 mm 2 /s; P G 0.0001Y0.05). The exceptions were transition zone cancers with a primary GG 4Y5 and a secondary GG 2Y3 or a primary GG 2Y3 and a secondary GG 4Y5 versus a degree 2 of prostatitis (P = 0.06Y0.09). No significant differences were found between subcategories of transition zone cancer primary and secondary GG (P = 0.17Y0.91) and between healthy transition zone without prostatitis versus both degree 1 and 2 prostatitis (P = 0.48Y0.94). In differences were present for cancer core lengths of, respectively, 10 Y e 12, 9 12 Y e 15 and greater than 15 mm for patients with primary GG 3 (P = 0.22Y0.87), 4 (P = 0.05Y0.84), and 5 cancers (P = 0.70Y0.91).
Receiver operating characteristic analysis for mADC to differentiate transition zone cancer cores (n = 87) from non-cancerous transition zone cores (n = 46) resulted in an AUC of 0.84 (95% CI, 0.77Y0.91). For the differentiation between the cancerous (n = 87) and non-cancerous cores with prostatitis (n = 55), the AUC also was 0.84 (0.77Y0.90). The AUC for differentiating the non-cancerous cores with any degree of prostatitis (n = 55) versus the non-cancerous cores without (n = 46) prostatitis was 0.56 (0.44Y0.67). The mADC had an AUC of 0.62 (0.49Y0.74) for the differentiation of primary GG 4Y5 (n = 39) from GG 2Y3 (n = 48) cancers.
DISCUSSION
Our results show that mADC values can differentiate the transition zone cancer from the non-cancerous transition zone (AUC 0.84) and from any degree of prostatitis (AUC 0.84). However, because of substantial overlap, mADC has a poor accuracy to distinguish primary GG 4Y5 from GG 2Y3 transition zone cancers (AUC 0.62) and cannot be used to differentiate between noncancerous transition zone with and without prostatitis (AUC 0.56).
Our significant mADC differences for transition zone cancer versus non-cancerous transition zone confirm findings in other studies. 8 /s) were in the lower range of these reported values. As we targeted cancer-suspicious regions using MRguided biopsy specimens as a reference standard, our ADC values may have been in the lower ranges of the former radical prostatectomyreferenced studies.
To our knowledge, one other study also used MR-guided biopsy specimens as a reference standard for diffusion-weighted imaging ADC. 10 Our significant mADC differences between degrees and 1 and 2 of prostatitis and most transition zone cancers confirmed the results of the latter study, in which a significant ADC difference between prostatitis and low-GG transition zone cancer was found (P G 0.001). 10 Inflammatory infiltrates in prostatitis lead to an increased cellular density and may therefore decrease ADC. 21 In a healthy transition zone, a large ADC variation may be present because of higher variability of the different tissue components with different cellular densities. Stromal benign prostatic hyperplasia has a more compact and more homogeneous cell density and is known to have lower ADC values (1.27 Â 10 j3 mm 2 /s) compared with glandular benign prostatic hyperplasia (1.73 Â 10 j3 mm 2 /s). 8 Therefore, a relative local ADC decrease due to focal chronic prostatitis may not be discerned in the transition zone. The higher the degree of the prostatitis is, the lower the mADC is, as is depicted in Figure 4 . Despite only including 5 cores with a degree 2 of prostatitis, we showed that, because of a lower ADC Gleason score is given on a core basis because some patients had different Gleason scores in different magnetic resonanceYguided prostate biopsy cores. Continuous parametric variables were compared with independent t tests. A significance level of P G 0.05 was used. *The Mann-Whitney test was used to evaluate the differences between continuous non-parametric variables.
†P values between the patients with magnetic resonanceYguided prostate biopsy specimens containing transition zone cancer versus the patients with magnetic resonanceYguided prostate biopsy specimens containing non-cancerous transition zone.
‡Numbers of MR guided biopsy core specimens. IQR indicates interquartile range; MRGB, magnetic resonanceYguided prostate biopsy; n.a., not applicable; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.
in a higher degree of prostatitis, a significant mADC difference between the magnetic resonanceYguided prostate biopsy (MRGB) specimen cores with degree 2 prostatitis (mADC, 1.12 Â 10 j3 mm 2 /s) versus the primary GG 4Y5 and secondary GG 2Y3 transition zone cancers and vice versa (histopathological categories II and III) did not exist (P = 0.06Y0.09). This significant mADC difference did exist for cores with a degree 1 prostatitis (mADC, 1.05 Â 10 j3 mm 2 /s), which had a higher ADC compared with any transition zone cancer (P G 0.0001).
Our 12 for differentiation of a radical prostatectomy specimen Gleason score higher than 6 versus 6 or lower in the transition zone using both mean ADC and tumor volume. Our moderate accuracy in differentiating primary GG 4 from GG 3 cancer cores was caused by mADC overlap between the GGs, which, itself, may have been the result of mADC variations. mADC variations may have been caused by the inclusion of a secondary GG core tissue and by inter-patient and intra-patient mADC variations. 24 Variation of the amount of noncancerous tissue in the cancer-containing cores did not cause significant mADC differences when we analyzed mADC for the primary GG 3 and 4 transition zone cancer cores with a cancer core length of 10Ye12, 912Ye 15, and 915 mm (P = 0.22Y0.87).
This study has limitations. First, our results are subject to selection bias. Because we used a cancer core length of 10 mm and greater, we excluded smaller cancers from our retrospective analysis. However, because MR-guided biopsy is performed in a larger patient group compared with patients undergoing surgery, still, less patient selection bias is present compared with radical prostatectomy specimens. Second, as mentioned, including secondary GG tissue that was different from the primary GG may have reduced accuracy of our differentiation of primary GG 4 from primary GG 3 cancers. Although present in a smaller volume compared with the primary GG, the presence of adifferent secondary GG causes variation and overlap in ADCs for primary GG. As mentioned earlier, our results clearly showed a larger ADC difference and less overlap for a secondary GG, which was identical to the primary GG compared with a secondary GG, which was different from the primary GG. Furthermore, inaccuracies in our measurements may have been caused by possible needle, prostate, or patient movement in the short time gap between the actual biopsy and the acquisition of confirmation scans. 25 Despite our manual registration of confirmation scans to the diffusionweighted imaging ADC maps, some variation in measurements due to patient movement throughout the whole MR-guided biopsy procedure may still have occurred. Third, we took into account a larger apparent size of the needle tip artifact on the MR images compared with the actual needle size. However, we did not adjust this measure for the angle of needle insertion with the static field (B0) of the MR scanner, which may influence the apparent needle size. 26 Fourth, because our reference standard MR-guided biopsy was based on targeting MR imaging cancer-suspicious regions, selection bias may have occurred. Cancer-suspicious regions may have a relatively higher cell density, resulting in lower ADC values compared with the whole transition zone.
To clinically apply our detected mADC differences for different histopathology entities in the transition zone, variation of ADC values should be reduced. In a recent study, correction for interpatient variation of healthy peripheral zone ADC significantly improved (P = 0.04; AUC, 0.91Y0.96) differentiation of GG 4 and/or 5 versus GG 2 and/or 3 cancers. 27 This principle may also be applied for cancers located in the transition zone.
In conclusion, mADC values can differentiate the transition zone cancer from the non-cancerous transition zone and from degree 1 and, sometimes, from degree 2 prostatitis. However, because of mADC overlap between the histopathology categories, mADC had a poor accuracy to distinguish between different subcategories of transition zone cancer primary and secondary GG and cannot be used for differentiation between non-cancerous transition zone with and without prostatitis. Diffusion-weighted MR imaging ADC may therefore contribute in the detection of transition zone cancers, but as a single functional MR imaging technique, diffusion-weighted MR imaging has a moderate diagnostic accuracy in separating higher versus lower GG components in transition zone cancers and in differentiating prostatitis from non-cancerous transition zone.
